North Carolina COVID-19 Agent-Based Model Framework for Hospitalization Forecasting Overview, Design Concepts, and Details Protocol
This Overview, Design Concepts, and Details Protocol (ODD) provides a detailed description of an agent-based model (ABM) that was developed to simulate hospitalizations during the COVID-19 pandemic. Using the descriptions of submodels, provided parameters, and the links to data sources, modelers will be able to replicate the creation and results of this model.
Code (1)
Similar Papers 제목 키워드 기반
Surveillance of COVID-19 Pandemic using Social Media: A Reddit Study in North Carolina
Coronavirus disease (COVID-19) pandemic has changed various aspects of people's lives and behaviors. At this stage, there are no other ways to control the natural progression of the disease than adopting mitigation strat…
named-entity-recognitionNamed Entity RecognitionNamed Entity Recognition (NER)NERMulti-Output Artificial Neural Network for Storm Surge Prediction in North Carolina
During hurricane seasons, emergency managers and other decision makers need accurate and `on-time' information on potential storm surge impacts. Fully dynamical computer models, such as the ADCIRC tide, storm surge, and …
Bayesian calibration of stochastic agent based model via random forest
Agent-based models (ABM) provide an excellent framework for modeling outbreaks and interventions in epidemiology by explicitly accounting for diverse individual interactions and environments. However, these models are us…
Dimensionality ReductionEpidemiologyAn early prediction of covid-19 associated hospitalization surge using deep learning approach
The global pandemic caused by COVID-19 affects our lives in all aspects. As of September 11, more than 28 million people have tested positive for COVID-19 infection, and more than 911,000 people have lost their lives in …
A Reanalysis of the FDA's Benefit-Risk Assessment of Moderna's mRNA-1273 COVID Vaccine: For 18-25-Year-Old Males, Risks Exceeded Benefits Relative to Hospitalizations
The FDA conducted a benefit-risk assessment for Moderna's COVID vaccine mRNA-1273 prior to its full approval (announced 1/31/2022). The FDA focused its assessment on males of ages 18-64 years because the agency's risk an…